DZANK1: Ankyrin Repeat-Containing Protein as a Drug Target and Biomarker

Target Name: DZANK1

NCBI ID: G55184

DZANK1

DZANK1: Ankyrin Repeat-Containing Protein as a Drug Target and Biomarker

Protein-coding genes have revolutionized our understanding of biology, leading to the identification of numerous diseases and their causes. One such gene is DZANK1, which encodes ankyrin repeat-containing protein (APC) with 20 exons. APCs are a class of transmembrane proteins that contain a unique repetitive amino acid sequence, known as ankyrin repeats, which plays a crucial role in their stability and functions. Despite the extensive research on APCs, the precise functions and potential therapeutic applications of DZANK1 remain poorly understood. This article will explore the biology of DZANK1, its potential as a drug target, and its potential as a biomarker for various diseases.

Understanding the Biology of DZANK1

DZANK1 is a 21-kDa protein that contains ankyrin repeats. The protein has a unique structure, with a long N-terminus that contains a variable region, a single transmembrane segment, and a C-terminus that contains a T-spine. The ankyrin repeats are located within the C-terminus, and their number and arrangement vary among different species.

Expression and Localization

DZANK1 is expressed in various tissues and organs, including brain, heart, lungs, liver, and pancreas. It is primarily located in the endoplasmic reticulum (ER), where it can be detected by immunofluorescence using antibodies specific for its ankyrin repeats. DZANK1 is also known to be expressed in various cell types, including epithelial cells, fibroblasts, and leukocytes.

Function and Potential Therapeutic Applications

The functions of DZANK1 remain poorly understood, but its potential as a drug target and biomarker are being investigated. One of the most promising avenues for research is the study of its potential as a therapeutic target for various diseases, including cancer.

DZANK1 has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues, and is a prime candidate for therapeutic intervention.

In addition to its role in cellular signaling pathways, DZANK1 has also been shown to be involved in the regulation of gene expression. Studies have shown that DZANK1 can interact with various transcription factors, including NF-kappa-B and SMAD3. This suggests that DZANK1 may be a negative regulator of gene expression, which could have implications for its therapeutic applications.

DZANK1 has also been shown to be involved in the regulation of cellular processes related to inflammation and fibrosis. Its expression has been shown to be elevated in various diseases, including cancer, and its function in these processes is under investigation.

Potential Biomarkers

DZANK1 has the potential to serve as a biomarker for various diseases, including cancer. Its expression has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that DZANK1 may be a useful biomarker for the diagnosis and treatment of these diseases.

In addition to its potential as a biomarker, DZANK1 may also serve as a drug target. Its involvement in various cellular processes and its potential functions as a negative regulator of gene expression make it an attractive target for small molecules and other therapeutic agents.

Conclusion

In conclusion, DZANK1 is ankyrin repeat-containing protein that has been shown to be involved in various cellular processes and has the potential as a drug target and biomarker for various diseases. Further research is needed to fully understand its functions and potential therapeutic applications.

Protein Name: Double Zinc Ribbon And Ankyrin Repeat Domains 1

The "DZANK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DZANK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets